HOVON 156

Name No. For Patients with Purpose
HOVON 156 19-16

Newly diagnosed diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with FLT3 mutations eligible for intensive chemotherapy

This trial will compare Gilteritinib and midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy


HOVON 150

Name No. For Patients with Purpose
HOVON 150 19-18

Newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy

This trial will compare ivosidenib and enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy


BCNI GMI-1271-301

Name No. For Patients with Purpose
BCNI GMI-1271-301 21-08

Relapsed/Refractory Acute Myeloid Leukemia (AML)

This Study is to Determine the Effficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukaemia